Search for a command to run...
<h2>Abstract</h2><h3>Background:</h3> A set of quality standards has been developed to help enhance the quality of healthcare provided to people living with axial spondyloarthritis (axial SpA) [1]. However, although the development of these standards did include a small sample of patients, overall, they reflect a predominantly clinical perspective about what good quality care for axial SpA looks like. Thus, there is a need for a substantive quantitative assessment of what patients' value and need from axial SpA services to provide a balancing view. In addition, there is a need to assess the extent to which patients' values and needs in axial SpA care are being met through current service provision. <h3>Objectives:</h3> To identify the experiences, values and needs of people living with axial SpA in the diagnosis and management of the condition. <h3>Methods:</h3> The National Axial Spondyloarthritis Society (NASS) commissioned Headstrong Thinking and Community Research to conduct a programme of research that explored patient experiences and views on what should be provided in the diagnosis and management of axial SpA. The extant literature and a small-scale qualitative study (n = 12) were used to inform the development of a UK-based online survey. The survey was distributed by NASS to people on the NASS e-news mailing list and advertised on social media (Facebook, Twitter and Instagram) between 4<sup>th</sup> February and 4<sup>th</sup> April 2022. Closed questions were mainly used to explore details of axial SpA and treatment, and the experiences of seeking a diagnosis, support after obtaining a diagnosis, and ongoing healthcare. <h3>Results:</h3> The online survey was completed by 939 participants. In total, 913 participants with a self-reported diagnosis of axial SpA were included. Many participants received a diagnosis over five years ago (69.2%) and 57.6% were female. For people diagnosed in the past five years (n = 294), over half of the participants received: access to a specialist rheumatology nurse (57%), information about prescribed medication (57%), and information about treatment course (51%) in the first year since receiving a diagnosis. However, less than half of the participants received: information about tailored physical exercises (40%), a tailored face-to-face National Health Service physiotherapy appointment (38%), or information on well-being (21%). Those who received support were largely very or quite satisfied (≥72% for each support, n=62-169). Many aspects of care were deemed very important to participants post-diagnosis (n = 913). Other than ‘information about physical exercises' (54%), less than half of participants described their experience of any other aspect of care as very or quite positive (see Figure 1). A similar pattern of response was seen when considering only those who were diagnosed within the past year (n = 57). Almost two-thirds of participants (61%) highlighted support with fatigue management and sleep, and pain management, as the most useful ways healthcare professionals (HCPs) can support them to self-manage (n = 913). Half (51%) of the participants wished for exercise/physical activity support, whereas almost a third (29%) desired counselling/mental health support. Figure 1Importance and experience of different aspects of care post-diagnosis (n = 913). <h3>Conclusion:</h3> There is a disconnect between what people living with axial SpA consider to be important in the management of their care and their experience of receiving care. Patients desire support with self-managing fatigue and sleep, pain, physical activity, and mental health. <h3>REFERENCES:</h3> [1] Kiltz U, Landewé RBM, van der Heijde D, Rudwaleit M, Weisman MH, Akkoc N, et al. Development of ASAS quality standards to improve the quality of health and care services for patients with axial spondyloarthritis. Ann Rheum Dis. 2020;79(2):193-201. <h3>Acknowledgements:</h3> <b>NIL</b>. <h3>Disclosure of Interests:</h3> Thomas Ingram NASS has received institutional grant funding from AbbVie, Biogen, Janssen, Lilly, Novartis and UCB, Jill Hamilton NASS has received institutional grant funding from AbbVie, Biogen, Janssen, Lilly, Novartis and UCB, Alison Hardy: None declared, Lucy Brady: None declared, Rachel Lopata: None declared, Alison Drury: None declared, Dale Webb NASS has received institutional grant funding from AbbVie, Biogen, Janssen, Lilly, Novartis and UCB. © The Authors 2025. This abstract is an open access article published in Annals of Rheumatic Diseases under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). Neither EULAR nor the publisher make any representation as to the accuracy of the content. The authors are solely responsible for the content in their abstract including accuracy of the facts, statements, results, conclusion, citing resources etc.